eculizumab   Click here for help

GtoPdb Ligand ID: 6884

Synonyms: h5G1.1 | h5G1.1VHC | Soliris®
Approved drug Immunopharmacology Ligand
eculizumab is an approved drug (FDA (2011), EMA (2007))
Compound class: Antibody
Comment: Eculizumab is a humanized monoclonal antibody targeting terminal complement activation, by binding to complement component C5 and inhibiting the production of C5a [4]. It is the first approved therapy for paroxysmal nocturnal hemoglobinuria.
Eculizumab's developers, Alexion Pharmaceuticals have developed a next-generation version of eculizumab called ravulizumab (ALXN1210; FDA approved in December 2018), that has a longer circulating half-life than the originator, which allows for monthly dosing.
The evidence confirming C5, C5a and the C5a receptor as anti-inflammatory and anti-cancer drug targets is reviewed by Horiuchi and Tsukamoto (2016) [2].

Biosimilars:
Amgen's biosimilar ABP 959 (Bekemv®) was approved by the EMA in April 2023.
Samsung Bioepis' biosimilar (SB12; Epysqli®) was approved by the EMA in May 2023.
BOW080 (Polpharma Biologics, formerly Epirus Biopharmaceuticals) was in development, but this project appears to have been discontinued.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2011), EMA (2007))
International Nonproprietary Names Click here for help
INN number INN
8231 eculizumab
Synonyms Click here for help
h5G1.1 | h5G1.1VHC | Soliris®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 37
Other databases
GtoPdb PubChem SID 178103466
PubChem SID 178103466
Search PubMed clinical trials eculizumab
Search PubMed titles eculizumab
Search PubMed titles/abstracts eculizumab
Wikipedia Eculizumab